title: Are leukocytes in salvaged washed autologous blood harmful for the recipient? The results of a pilot study.
abstract: To explore whether polymorphonuclear leukocytes (PMNL) are activated to the priming threshold through intraoperative blood salvage, and are thus able to induce endothelial damage, we investigated chemotactic response (n = 20) and respiratory burst (RB; n = 20) of PMNL without (basal respiratory burst, bPMNL-RB) and after in vitro stimulation with formyl-Met-Leu-Phe (fMLP-RB) and phorbol myristate acetate (PMA-RB). Blood was processed with a continuous autotransfusion device (CATS). Heparin (Heparin group) and sodium citrate (Citrate group) were used alternately as an anticoagulant for each half of the chemotaxis and RB studies. Comparison of measurements from the processed autologous erythrocyte concentrates (paEC) to pre- and intraoperative arterial blood samples showed no statistically significant difference for any test of PMNL functional responses in an orthopedic patient population. Analysis of intraindividual changes demonstrated a significantly increased bPMNL-RB (both groups, P = 0.0032; Heparin group, P = 0.0098), fMLP-RB (both groups, P = 0.0484; Citrate group, P = 0.0371), and PMA-RB (Citrate group, P = 0.002) in the paEC compared with intraoperative arterial samples, whereas the chemotactic response did not change. Nevertheless, median values of all RB measurements in the paEC were within the range of pre- and intraoperative values, indicating that PMNLs contained in the paEC are neither impaired nor activated to the priming threshold. The results confirm the clinical experience that intraoperative blood salvage is safe to use during major orthopedic surgery and questions the beneficial effect of special leukocyte-removing filters.
authors.affiliation: Department of Anesthesia and Critical Care Medicine, The Leopold-Franzens University of Innsbruck, Innsbruck, Austria. Petra.Innerhofer@uibk.ac.at
authors.forename: P
authors.initials: P
authors.lastname: Innerhofer
authors.forename: F J
authors.initials: FJ
authors.lastname: Wiedermann
authors.forename: W
authors.initials: W
authors.lastname: Tiefenthaler
authors.forename: W
authors.initials: W
authors.lastname: Schobersberger
authors.forename: A
authors.initials: A
authors.lastname: Klingler
authors.forename: C
authors.initials: C
authors.lastname: Velik-Salchner
authors.forename: E
authors.initials: E
authors.lastname: Oswald
authors.forename: E
authors.initials: E
authors.lastname: Salner
authors.forename: E
authors.initials: E
authors.lastname: Irschick
authors.forename: G
authors.initials: G
authors.lastname: Kühbacher
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D001804:Blood Transfusion, Autologous / Q000009:adverse effects*; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002648:Child; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007432:Intraoperative Period; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000502:physiology*; D010865:Pilot Projects; D016897:Respiratory Burst / Q000187:drug effects
chemical_list: D000925:Anticoagulants; D006493:Heparin